ANT-GROUP
5.3.2024 12:28:33 CET | Business Wire | Press release
For the third consecutive year, Ant Group, a global digital technology provider, has been recognized as a Top 100 Global Innovator™ 2024 by Clarivate™, a global leader in connecting people and organizations to intelligence they can trust to transform their world. This recognition reaffirms Ant Group's ongoing commitment to innovation excellence in technologies such as artificial intelligence (AI) and blockchain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305020027/en/
Clarivate recognizes Ant Group as one of the Top 100 Global Innovators 2024 (Graphic: Business Wire)
Gordon Samson, President, Intellectual Property, Clarivate, said, “We congratulate Ant Group for being named as a Top 100 Global Innovator again. To feature as a Top 100 Global Innovator is no mean feat as maintaining an edge in the innovation ecosystem is harder than ever. Organizations must balance experimentation and risk with discipline and reward. We measure and rank innovative performance in a dynamic and thorough way, using live thresholds of differentiation. At Clarivate, we think forward by analyzing the quality of ideas, their potency and their impact to identify the world’s top innovators, and this year we reveal the ranking of these innovators for the first time.”
As of the end of 2023, Ant Group had filed 32,459 patent applications globally, with 22,102 patents granted. The top three categories of these patent applications are security technology, blockchain and AI.
"Our recognition by Clarivate as one of the Top 100 Global Innovators is a testament to our innovation capabilities," said Shen PAN, Director of Patents at Ant Group. "We are committed to leveraging technology to build trust and accelerate digital transformation across industries. Our journey is driven by our advancements in key technologies such as blockchain, privacy computing, security technology, Internet of Things (IoT) databases, and most notably, AI.”
In the field of AI, Ant Group has been continuously leveraging its technology to enhance the user experience across its product offerings for years. As of the end of 2023, Ant Group had filed over 3,000 AI-related patents. During Alipay’s 2024 Chinese New Year campaign, AI features in the app attracted 600 million interactions.
To facilitate technological advancement across industries, Ant Group has been making its innovations publicly accessible to developers in the open-source community. For example, Ant Group’s AI infrastructure team open-sourced ATorch, an extension library of PyTorch, that can improve GPU utilization rate up to 60% in large-scale pre-trainings of Large Language Models (LLMs). Meanwhile, the company’s open-sourced Lookahead achieves lossless generation accuracy for LLMs while boosting the inference speeds of LLMs by 2 to 6 times.
By the end of 2023, the number of open-source repositories from Ant Group on platforms such as GitHub had exceeded 1,900. Additionally, according to the 2023 Blue Paper on the Development of Open Source in China published by China OSS Promotion Union (COPU), Ant Group is recognized as one of the top three organizations in the country in terms of open-source contributions and influence.
Leveraging its innovations in technologies such as blockchain, privacy computing, security technology, IoT, and databases, Ant Group provides technology products and services to support the digital transformation and collaboration of global enterprise customers across a variety of industries. These industries include banking, telecommunication, real estate, medicine and energy. The company has garnered recognition from various organizations for its excellence in delivering innovative products and services to customers. For example, AntChain was recognized by Forbes on the Blockchain 50 list for five consecutive years (from 2019 to 2023). In September 2023, ZOLOZ was named as a Representative Vendor for the second consecutive time in the latest Gartner Market Guide for Identity Verification.
Methodology
The Top 100 Global Innovators uses a complete comparative analysis of global invention data to assess the strength of every patented idea, using measures tied directly to their innovative power.
To move from the individual idea strength to identify the organizations that create them more consistently and frequently, Clarivate sets two threshold criteria that potential candidates must meet and then adds a measure of their patented innovation output over the past five years.
For full information on the methodology used to identify the 2024 list, see here.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
About Ant Group
Ant Group traces its roots back to Alipay, which was established in 2004 to create trust between online sellers and buyers. Over the years, Ant Group has grown to become one of the world's leading open Internet platforms.
Through technological innovation, Ant Group supports its partners in providing inclusive, convenient digital life and digital financial services to consumers and SMEs. In addition, it has been introducing new technologies and products to support the digital transformation of industries and facilitate industrial collaboration. Working together with global partners, the company enables merchants and consumers to make and receive payments and remit around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305020027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
